Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells

Drug Development and Industrial Pharmacy

Volumn 43, Issue 1, 2017, Pages 12-21

  Küçüktürkmen, Berrin ^a   Devrim, Burcu ^a   Saka, Ongun M ^a   Yilmaz, Şükran ^b   Arsoy, Taibe ^b   Bozkir, Asuman ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Foot and Mouth Disease Institute   (Turkey)

Author keywords

Co delivery; lipid polymer hybrid nanoparticles; microRNA 21; pemetrexed; PLGA; U87MG cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPID POLYMER HYBRID NANOPARTICLE; MICRORNA 21; NANOCARRIER; PEMETREXED; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID; NANOPARTICLE; POLYMER;

ANTISENSE THERAPY; ARTICLE; CELL NUCLEUS; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DISPERSITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; EMULSION; EVAPORATION; GAMMA RADIATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE AREA; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; DOSE RESPONSE; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; LIPIDS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PEMETREXED; POLYMERS;

EID: 84976412156     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639045.2016.1200069     Document Type: Article

References (52)

1. Pourgholi F, Hajivalili M, Farhad JN, et al. Nanoparticles:novel vehicles in treatment of glioblastoma. Biomed Pharmacother 2016;77:98–107.
2. Wen PY, Kesari S., Malignant gliomas in adults. N Engl J Med 2008;359:492–507.
3. Garg T, Bhandari S, Rath G, Goyal AK., Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target 2015;23:865–87.
4. Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces 2015;7:6674–82.
5. Nance E, Zhang C, Shih TY, et al. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano 2014;8:10655–64.
6. Ricci M, Blasi P, Giovagnoli S, Rossi C., Delivering drugs to the central nervous system:a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006;13:1757–75.
7. Chaichana KL, Pinheiro L, Brem H., Delivery of local therapeutics to the brain:working toward advancing treatment for malignant gliomas. Ther Deliv 2015;6:353–69.
8. Shilo M, Motiei M, Hana P, Popovtzer R. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale 2014;6:2146–52.
9. Neha B, Ganesh B, Preeti K., Drug delivery to the brain using polymeric nanoparticles:a review. Int J Pharm Life Sci 2013;2:107–32.
10. Kreuter J., Drug delivery to the central nervous system by polymeric nanoparticles:what do we know? Adv Drug Deliv Rev 2014;71:2–14.
11. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 2012;161:264–73.
12. Cheow WS, Hadinoto K., Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces 2011;85:214–20.
13. Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine 2013;9:474–91.
14. Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 2013;7:2056–67.
15. Devulapally R, Sekar NM, Sekar TV, et al. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano 2015;9:2290–302.
16. Olivier JC., Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108–19.
17. Sah H, Thoma LA, Desu HR, et al. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine 2013;8:747–65.
18. Wang L, Hao Y, Li H, et al. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system:Angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles. J Drug Target 2015;23:832–46.
19. Misra R, Acharya S, Dilnawaz F, Sahoo SK., Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond) 2009;4:519–30.
20. Hanauske AR, Chen V, Paoletti P, Niyikiza C., Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363–73.
21. Paz-Ares L, Bezares S, Tabernero JM, et al. Review of a promising new agent-pemetrexed disodium. Cancer 2003;97:2056–63.
22. Dai H, Chen Y, Elmquist F., Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 2005;315:222–9.
23. Sorensen JB., Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011;7:919–28.
24. Griveau A, Bejaud J, Anthiya S, et al. Silencing of miR-21 by locked nucleic acid–lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. Int J Pharm 2013;454:765–74.
25. Guz M, Rivero-Müller A, Okon E, et al. MicroRNAs-role in lung cancer. Dis Markers 2014:218169.
26. Chistiakov DA, Chekhonin VP., Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol 2012;684:8–18.
27. Ren Y, Kang CS, Yuan X, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2010;21:303–14.
28. Qian X, Ren Y, Shi Z, et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolamide and miR-21 inhibitor gene therapy. Mol Pharmaceutics 2012;9:2636–45.
29. Costa PM, Cardoso AL, Mendonça LS, et al. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells:a promising system for glioblastoma treatment. Mol Ther Nucleic Acids 2013;2:e100.
30. Zhi F, Dong H, Jia X, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One 2013;8:e60034.
31. Devulapally R, Sekar TV, Paulmurugan R., Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells. Mol Pharmaceutics 2015;12:2080–92.
32. Ananta JS, Paulmurugan R, Massoud TF., Nanoparticle-delivered antisense microRNA-21 enhances the effects of temozolomide on glioblastoma cells. Mol Pharmaceutics 2015;12:4509–17.
33. Bai H, Xu R, Cao Z, et al. Involvement of miR-21 in resistance to daunorobicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011;585:402–8.
34. Davis S, Lollo B, Freier S, Esau C., Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294–304.
35. Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010;101:948–54.
36. Bishi DK, Mathapati S, Venugopal JR, et al. Patient-inspired ex vivo liver tissue engineering approach with autologous mesenchymal stem cells and hepatogenic serum. Adv Healthcare Mater 2016;5:1058–70.
37. McCloy RA, Rogers S, Caldon CE, et al. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 2014;13:1400–12.
38. Schubert MA, Muller-Goymann CC., Characterisation of surface-modified solid lipid nanoparticles (SLN):influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005;61:77–86.
39. Chiarelli PA, Kievit FM, Zhang M, Ellenbogen RG., Bionanotechnology and the future of glioma. Surg Neurol Int 2015;6:S45–58.
40. Celia C, Cosco D, Paolino D, Fresta M., Nanoparticulate devices for brain drug delivery. Med Res Rev 2011;31:716–56.
41. Chen YS, Alany RG, Young SA, et al. In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides. Drug Deliv 2011;18:493–501.
42. Fattal E, Couvreur P, Dubernet C., “Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 2004;56:931–46.
43. Cheng X, Lee RJ., The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev 2016;99:129–37.
44. Dillen K, Weyenberg W, Vandervoort J, Ludwig A., The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles. Eur J Pharm Biopharm 2004;58:539–49.
45. Chen M, Gao S, Dong M, et al. Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery. ACS Nano 2012;6:4835–44.
46. Alimohammadi S, Salehi R, Amini N, Davaran S., Synthesis and physicochemical characterization of biodegradable PLGA-based magnetic nanoparticles containing amoxicillin. Bull Korean Chem Soc 2012;33:3225–32.
47. Vázquez-Blomquist D, Fernández JR, Miranda J, et al. Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG. Mol Biol Rep 2012;39:11167–75.
48. Lu N, Liu Q, Li R, et al. Superior antimetastatic effect of pemetrexed-loaded gelatinase-responsive nanoparticles in a mouse metastasis model. Anticancer Drugs 2012;23:1078–88.
49. Clawson C, Ton L, Aryal S, et al. Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered PEG shedding. Langmuir 2011;27:10556–61.
50. Costa PM, Cardoso AL, Custódia C, et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib:a new multimodal gene therapy approach for glioblastoma. J Control Release 2015;207:31–9.
51. Song MS, Rossi JJ., The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. Front Genet 2014;4:1–12.
52. Corsten MF, Miranda R, Kasmieh R, et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell-derivated S-TRAIL in human gliomas. Cancer Res 2007;67:8994–9000.